Skip to main content

ERC

News
  • Participate
    • Patients
    • Doctors
    • Investors
  • Products
    • Gliovac/ERC1671
  • Media
    • News
    • Publications
  • About
    • Executive Management
    • Executive board
    • Scientific board
    • Milestone achievements
  • Contact
NewsPublications
31Aug2018

12 month progress report 31/08/2017-31/09/2018

ERC has made significant progress over the past 12 months in moving our experimental vaccine Gliovac (also know as ERC1671) toward commercialization.
08Jul2016

New production site in the Netherlands

ERC has opened a new additional production site in the Netherlands dedicated to GMP-based production of Gliovac/ERC1671/SITOIGANAP against glioblastoma brain cancer, as well as vaccines based on the...
15May2016

Approval for open phase II study

ULB Belgium’s ethical commitee has approved the protocol for an open phase II study of standard treatments in combination with Gliovac/ERC1671/SITOIGANAP vs...
29Mar2016

Interest to use our technology for other cancers

Based on the visibility of preliminary results for GBM, independent groups expressed their strong interest to use the technology for other cancers.

Pages

  • « first
  • 1
  • 2
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Cookie and Privacy Policy for more details.
Close
Copyright © 2001-2025 ERC.SA. All rights reserved.
Made byKonnu
Cookie and Privacy PolicyTerms & Conditions
Top